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Abstract 
Background: The PICC is a central venous system inserted in the peripherally vein. The central peripheral catheter 
catheter system (PICC=peripherally inserted central catheters) is a widely used procedure in clinical practice by 
medical and nurse team. PICC has potential complications that are rare but not entirely irrelevant. It is used for 
continuous and discontinuous treatment and, after a correct insertion procedure, it can be used for a period of time 
between 1 week to 3 months. The last-generation dispositive has an high-biocompatibility due to the high quality of 
the materials (silicone or polyurethane), a total length of 40-60 cm and a diameter between 16 to 25 Gauge or 2 to 5 
French. 
 
Aims: The aim of our study is to evaluate the trombotic risk related to the positioning of the device in relation to the 
individual risk factors. Therefore we have elaborated the CoRaMaPicc protocol that allows, based on the 
preliminary data evaluation, to reduce the trombotic risk in patients with high cardiovascular risk profile. 
 
Methods: The study has started in July 2016. We have enrolled 30 patients (18 males and 12 females with range age 
of 30-99 yrs and mean age of 82+13,5 yrs). Enrolled patients have Body mass Index  or (BMI) with range from 
16,3-26,5 Kg/mq and mean BMI value of 23,5+2,5 Kg/mq. Enrolled patients were subjected to laboratory 
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assessment of cardiovascular risk factors like laboratory assessment of Methyl-Tetra-Hydro-Folate-Reductase or 
(MTHFR) and Homocysteine, Fibrinogen, D-Dimer, International Normalized Ratio (INR), Prothrombin Time (PT), 
activated Partial Thromboplastin Time (aPTT), Platelets (PLT), trombotic risk evaluation (CHA2DS2-VASc Score), 
and bledding risk evaluation (HAS-BLED Score). Before the insertion procedure of the PICC, single or duble lumen 
(Groshong or Power PICC type), the patient were subjected to a preliminary ultrasound and echo-doppler vein 
evaluation to underline the presence of atipical anatomical state of the patients veins. After the procedure the 
patients were subjected to second ultrasound and echo-doppler vein evaluation and then to a radiographic 
examination to verify the correct position of the PICC. All patients were enrolled for follow- Up to evaluate 
trombotic complications. Statistical analysis was performed using the Survival Analysis test to evaluate the patients 
during the follow-up period in relation to thrombotic events. The data obtained from our study have been described 
taking also into account the data present in the international literature.   
 
Setting: The study was performed  using a specific setting in a room  of the Internal Medicine Department of the 
Alfredo Fiorini Hospital (Terracina, Italy), guarantee an aseptic procedure , the right comfort for the patients and the 
appropriate privacy. 
 
Discussion: More data in the literature underline the presence of non-eliminable risk factors like anatomic state of 
the patients vein that can play a variable role of procedural risk factor and can predispose to procedural or post-
procedural complication after the implantation procedure. In specific cases it is difficult to asses an echo-doppler 
examination of heart for meteorism or ascites and radiographic exams for the presence of pleural effusion. The 
CoRaMaPiCC protocol use different technique to explore the post-insertion period and the follow-up time at 12 
week. In case of meteorism or ascites the ultrasound examination of the heart cameras was replaced by the 
radiographyc evaluation while in case of pleural effusion, the evaluation of the device position was deduced using 
the only ultrasound approach (when the vein system is explorable). Procedural algorithm utilized in our implant 
protocol allows to improve the diagnostic capabilities of the conditions that can predispose to thrombotic 
complications. During the study period (1 year), the PICCs were removed for death (7 patients; 4 patients for 
irreversible heart disease, 1 patient for cardiogenic shock 1 patient for septic shock and 1 patient for Creutzfeld-
Jacob disease), for spontaneously remotion (1 patient for low compliance of the patient) and for end of therapy (22 
patients). The presence of cardiovascular risk factors alone is not sufficient for determining statistically significant 
changes in the thrombotic risk. As reported historically by the description of the wirkow triad, the presence of three 
clinical signs, and in particular the presence of endothelial damage (functio lesa) is a sine qua non condition for the 
occurrence of thrombotic episodes.  
 
Conclusion: The CoRaMaPicc protocol allows, based on the evaluation of the data, to minimize endothelial damage 
and therefore to reduce the incidence of the wirchof's triade related with an high  trombotic risk. The data were 
elaborated considering the different thrombotic risk linked to the presence of the homozygous MTHR mutation 
responsible for the increase of homocysteine values and therefore of the further thrombotic risk.  Further studies are 
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needed to expand the number of enrolled patients and increase the follow-up period. Our data give comfortable 
results but further evaluation are needed to have conclusive results. 
 
Keywords: PICC; Peripherally inserted central catheters; Trombotic risk; CoRaMaPIcc protocol 
 
1. Introduction 
In hospital the absence of venous access led us to use a Peripherally Inserted Central Catheter (PICC) for continuous 
or discontinuous use for a period of time between 1 week to 3 months. The inserction of this device is significantly 
increased, because PICC is considered a safety method for long-term administration of Antibiotics, total parenteral 
nutrition or chemotherapy in frailty patients. In the 1070s , the poor quality of the materials (polyethylene or first-
generation polyurethanes) caused an excessive level of complications. In the early 1990s, the new material (silicone) 
represented a new alternative for the progressive affirmation of peripheral central venous access. GAVeCeLT 
identified, in 2005, four possible causes of reduced use of PICC: (poor knowledge, by doctors and nurses, of the 
correct indications of such presidencies; the lack of training courses focused on the implant and the management of 
PICC; the poor diffusion of ecoguided technique, in other words;. Nurses opinion about the PICC implant (did not 
regard their professional profile). For these reasons, in recent years, PICCs are widely used particularly in North 
America and, most recently, in continental Europe [1]. 
 
1.1 PICC Classification 
For the PICC timing on site the guidelines have distinguisced 
 Short term CVC:<4 weeks (peripheral; material: teflon) 
 Medium term CVC:<1-6 months (PICC, midline, cvc; material: silicone ) 
 Long-term CVC:>1-6 months CVCs (Groshong or Hickman) and fully implantable CVCs (port-a-cath) 
 For the presence of antimicrobial or antiseptic drugs the guidelines have distinguisced dispositive with 
chlorhexidine/silver or sulfadiazine; minocycline/rifampicin; (to prevent infections) and platinum/silver [2]. 
 
1.2 Indication to PICC insertion  
Directions for PICC The insertion of a PICC is consistent with: Need for infusion of acid solutions (pH<5) or basal 
(pH>9) or hypertonic (osmolarity>800 mOsm/l), or with irritating effect on the endothelium Need for measuring the 
Central Venus Pressure high risk of mechanical complications when a CVC is inserted in the internal or succulent 
jugular vein (obese patients, patients with anatomical and/or pathological disorders of the neck, patients with severe 
coagulopathy); presence of high risk of infectious complications if it is placed a traditional CVC (tracheotomy 
patients, immunodepressed or high-risk bacteria patients); Situations where it is logistically difficult or expensive to 
proceed to the placement of a traditional CVC (domicile, lack of a dedicated team, etc); need for central venous 
access for particularly prolonged time ('mid-term':<3 months); Need for medium central venous access (<3 months) 
in the patient to be treated either exclusively or in the field outside the hospital; Need for medium central venous 
access (<3 months) to be used either exclusively or discontinuously. 
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PICC is contraindicated in the following situations: Note or suspect bacterium or septicaemia; Prevents irradiation of 
the intended insertion site; Pregnant venous thrombosis episodes or vascular surgery interventions at the planned 
positioning site; Local factors that can prevent proper device stabilization or access (erythema, edema or eczema); 
Insufficient body size of the patient compared to the implant size. However, in patients undergoing infusional 
therapy over five days, an opportunity to use a long-term intravascular catheter, such as PICC, should be considered, 
based on evaluation criteria related to the characteristics of infusions over to the availability of the peripheral 
vascular vein, necessary to guarantee the therapeutic continuity and the efficiency of the infusive system [2]. 
 
1.3 Risk factors due to PICC implantation 
Data presented in the literature underline that the incidence of complications associated with Picc insertion is 
between 3% and 38% of cases and the complications can be due to different factors, including the trauma of the 
vascular wall caused by the insertion of the catheter,  the endothelial abrasion caused by the movement of the 
catheter or the Kinking due to the torsion of the catheter; and the pinch-off syndrome due to CVC compression 
between the clavicle and the first rib when PICC is inserted into the succlavia vein. Another aspect to consider is the 
thrombotic adjunctive risk due to the number of manipulations and the quality of the management procedure of the 
catheter.  
 
2. Aim 
The aim of the study is to evaluate the thrombotic risk associated with the positioning of the device. We have 
developed the CoRaMaPicc protocol which allows to reduce the thrombotic risk due to PICC insertion [3] in 
patients with high cardiovascular and trombotic risk. 
 
3. Materials and Methods 
We have enrolled 30 patients (18 males and 12 females with range age 30-99 yrs and mean age of 82+13.5 yrs). 
Enrolled patients have Body mass Index  or BMI with range from 16.3-26.5 Kg/mq and mean BMI value of 
23.5+2.5 Kg/mq. Enrolled patients were subjected to laboratory assessment of cardiovascular risk factors like 
laboratory assessment of Methyl-Tetra-Hydro-Folate-Reductase or (MTHFR) (Figure 1a) and Homocysteine (Figure 
1b), Fibrinogen (Figure 2a), D-Dimer, International Normalized Ratio (INR) (Figure 2b), Prothrombin Time (PT), 
activated Partial Thromboplastin Time (aPTT), Platelets (PLT), trombotic risk evaluation (CHA2DS2-VASc Score) 
(Figure 3a and Table 1) and bledding risk evaluation (HAS-BLED Score) (Figure 3b and Table 2). All patients 
enrolled have high cardiovascular risk profile in 90% of cases and low or moderate risk profile in 10% of cases and 
have high value of blood pressure. All patients had undergone pre-insertion phase, at an ultrasound evaluation.  
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Figure 1a-1b: Methyl-Tetra-Hydro-Folate-Reductase (MTHFR) and Homocysteine profile of enrolled patients. 
 
Figure 2a-2b: Fibrinogen and International Normalized Ratio (INR) profile of enrolled patients. 
 
Figure 3a-3b: CHADS-VASC and HAS-BLED evaluation of enrolled patients. 
 
Condition  Points 
 C  Congestive heart failure (or Left ventricular systolic dysfunction) 1 
 H 
Hypertension: blood pressure consistently above 140/90 mmHg (or treated hypertension on 
medication). 
1 
 A2 Age ≥75 years 2 
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 D Diabetes Mellitus 1 
 S2 Prior Stroke/TIA/Thromboembolism 2 
 V Vascular disease (e.g. peripheral artery disease, myocardial infarction, aortic plaque) 1 
 A Age 65–74 years 1 
 Sc Sex category (i.e. female sex) 1 
 
Table 1: HAS-BLED Score (acronym of the major factors associated with ischaemic stroke risk in patients with 
atrial fibrillation). 
  Condition Points 
H Hypertension -( systolic blood pressure >160 mmHg)                                                              (Points: 1) 
A 
 
Abnormal renal function (defined as the presence of chronic dialysis or renal 
transplantation or serum creatinine 200µmol/L (>~2.3 mg/dL))       (Points: 1) 
A 
 
 
Abnormal liver function ( defined as chronic hepatic disease (eg. cirrhosis) or biochemical  
evidence of significant hepatic derangement (eg. bilirubin >2x upper limit of normal, in 
association with AST/ALT/ALP >3x upper limit normal)                                                                                       (Points: 1)
S Stroke (Previous history of stroke)                                                                                               (Points: 1) 
B Bleeding (Major bleeding history (anemia or predisposition to bleeding))                                  (Points: 1) 
L Labile INRs (refers to unstable/high INRs or poor time in therapeutic range(eg<60%))            (Points: 1) 
E Elderly (age >/= 65)  (Points: 1) 
D Drug Therapy (concomitant therapy such as antiplatelet agents, NSAID's)                               (Points: 1) 
A Alcohol intake (consuming 8 or more alcoholic drinks per week)                                              (Points: 1) 
 
Table 2: HAS-BLED Score (acronym of the major factors associated with bleeding risk in patients  receiving oral 
anticoagulation). 
3.1 Preliminary vein evaluation 
PICC positioning require, for a correct positioning, of the availability of a large gauge vein like Succlavia, internal 
or external jugular, femoral, Cephalic, external jugular vein, internal jugular vein or saphenous vein because alarge 
diameter of the vein reduce the endothelial damage and therefore reduce the risk of vascular disease and thrombotic 
events due to all causes. The recommended plant technique is that for percutaneous venipuncture [4, 5]. 
 
3.2 CoRaMaPiCC executive protocol 
NAVAN recommends that the most appropriate position for the PICC tip is the lower third of the Upper Cave Vein 
near the junction between the latter and the right atrium. This tip position allows the catheter to float free within the 
lumen of the vein and reduce the percentage of complications such as thrombosis and infections [6]. A specific 
setting has been created to provide a better PICC positioning procedure with good patient comfort and to warranty 
an aseptic procedure. The skin preparation should be made with 2% chlorhexidine in an alcoholic solution by 
carefully scrubbing the area. The 2% chlorhexidine solution in 70% isopropyl alcohol isvused with a monodose 
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applicator. The procedure for the implant was carried out in echo-guidated mode by preparing the ultrasound device 
with sterile washers. 
 
3.3 Study of the patient's veins 
The doctor with adeguate trainer period, after relative acquisition of  certification and authorization, can study the 
veins of the arm and neck, with an ultrasound echo-doppler. The purpose of this examination is  diagnostic and 
semiological, and gives us the possibility to underline the presence of a linear pathway of the vein of the arm 
(basilica, cephalic or brachial) in order to receive a venous catheter and esclude the presence of a thrombotic 
disease.  Frequently, the veins of the dominant arm (predominates), have a greater caliber and the more frequent use 
during the movements reduce the risk of thrombosis. A second choice can be the brachial vein because it shows, 
generally, a smaller diameter than the basilica vein and has a greater number of valves. The third choice is the 
cephalic vein because it has a smaller linear pathway and a significant increase of number of the valves. In obese 
patients, however, the basilic vein becomes the third choice, because it is anatomically located more deeply than the 
cephalic vein, therefore the cephalic vein becomes the first choice (superficial vein).  
 
The venipuncture site should be calculated by evaluating: the size of the vein, the number of the valves and the 
position of the vein compared to the artery. The insertion site of the catheter must be a sufficiently isolated area and 
it is adeguate to warranty a lower risk of infection. The diameter of the catheter should be about one-third of the 
diameter of the vein and, in cases where this rule cannot be observed, the catheter gauge should not exceed 50% of 
the diameter of the vein. The diameter of the venous vessel is expressed in mm and the catheter in Fr (French). The 
calculation is made considering that 1 mm equals to 3 Fr. 
 
3.4 Ecoguided venipuncture 
The venipuncture of a deep vein (basil or brachial) is the standard venous  technique for positioning a PICC, 
associating with enormous benefits in terms of safety, cost-effectiveness and efficiency. ESPEN Guidelines- 
European Society of Parenteral and Enteral Nutrition, recommended the constant use of ECU and the use of Micro-
insertion procedure (Seldinger modified technique). The appropriateness of the training received is the most 
important factor to determinate a successful procedure. Similar evaluations can be referred to the quality of the 
ultrasound examination that require a clear visualization of the median nerve and the quality of the micro-insertion 
kit. A too rigid metal guide or a mediocre micro-introducer are associated with failures even in expert hands. 
 
When the catheter is positioned, it is easy to visualize into the vein with ECU and a simple compression with the 
hand or the ultrasound probe to facilitate the passage of the catheter from the succlavia vein to avoid the giugular 
vein involvment. Alternatively, if  the patient is collaborative, it is possible to turn the head versus the operator side 
to have a good giugular vein compression and avoid malposition. After the maneuver, it is recommended to check 
with the ultrasonic probe the absence of the catheter in both jugular veins. This easy and simple procedure allows to 
immediately identify potential catheter malpositions. At the end of the implant operation, the patient was studied 
ultrasonically with a linear probe  in a longitudinal section from the apex to the bases of the lung for pneumothorax 
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search and with longitudinal and transverse section, integrating with the power-doppler method, to evaluate the 
possible malposition of the catheter into the vein. A Convex probe was used for the evaluation of the cardiac cavities 
using an epigastric window section (under the xifoid process) and a subcostal section. Finally, the radiography of the 
chest has been performed as well as guidelines to confirm the exact positioning of the device. At the end of these 
operations, the patient was subjected to follow-up for thrombosis due to high cardiovascular risk profile or 
endothelial damage related to the insertion procedure. 
 
All patients received daily wash-out, with 5 cc (ml) of saline solution using a 10 cc (ml) syring type, into the PICC 
or an added wash-out after any pharmacological treatment. We have used standard instruments to register ECU. The 
statistical analysis was performed using Sigmastat Analysis Program (version 3.5) and Survival Analysis Test 
(Figure 4) to analize the number of the thrombotic events in all enrolled patients during the follow-up period. 
 
3.5 Study design 
All the patients provided a written informed consent. The Study is caratherized by a run-in period during which all 
patients have undergone laboratory exams pre-insertion procedure to underline a thrombotic disease and then have 
undergone a follow-up evaluation (Figure 4). The study started in July 2016. We have enrolled 30 patients (18 males 
and 12 females with range age 30-99 yrs and mean 82+13.5 yrs).  An alteration of the coagulation values due to 
anticoagulant treatment are not a contraindication to the PICC implant but should be known to eventually make a 
more enduring and accurate compression of the venipuncture zone. The presence of thrombotic processes may be an 
absolute contraindication to the inserction of  central venous system like the PICC. Presence of Pace Maker/ 
Defibrillator; It is necessary to ascertain whether the patient is carrying a Pace Maker or other device on one side of 
the trunk as it indicates the need to implant the venous access from the opposite side; Possible allergy to the 
administration of anesthetic. The presence of burns in the arms at the insertion level is an absolute contraindication 
to the PICC implant. 
 
3.6 Study limitations 
The limit of the study can be actually related to the number of patients (30 patients) enrolled in the CoRaMaPicc 
study and currently in follow up. This limitation imposes an obligation to describe the study data in terms of 
preliminary data requiring further investigation.  
 
3.6.1 Study patients: Elegibility requirements at screening included age of at least 18 years. Exclusion criteria 
included presence of trombosis or septic vascular disease. 
 
3.6.2 Study procedures: Patients who had no trombosis or septic vascular disease were assigned to the study group. 
Patients were evaluated during the first day (and during the follow-up phase if required) and then after 1-3 month. 
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3.7 Data management 
The data collection was performed at the same time as also the informed consent request for positioning of 
peripheral venous access. Scale utilization has been aligned with the international referencing system for laboratory 
examinations and instrumental examinations. 
 
3.7.1 Study outcome: The primary outcome was the trombotic risk evaluation after the dispositive inserction 
(Figure 4) with a clinical summary score (in a scale from 0 to 1, with lower scores indicating absence of trombosis 
due to the implantation procedure) in patients with different genetic profile (Figure 1a-b) and CHAD-VASC OR 
HASBLED score (Figure 3a-b). 
 
3.7.2 Statistical analysis: The data collection has been done by integrating the paper material with a database 
specifically created for inserting the laboratory data and the instrumental examinations associated with the 
procedure. The need to create a database is linked to the ability to perform preliminary data analysis using simple 
"filter" functions and to control the integrity of the data entered and to export the data in a mode compatible with the 
statistical analysis software performed with Sigmastat VERSION 3.5 for WindowsXp. 
 
3.8 Data elaboration 
Preliminary data has shown that genetic factors, while having an internationally recognized prothrombotic role, are 
not alone sufficient to discriminate against post-implant thrombotic risk, but must be framed in the primum movens 
that may be sought in mechanical and/or chemical endothelial traumas And in inadequate device management 
(especially for PICCs, which, being not tunneled, are subjected to a higher risk of thrombotic complications) [7]. We 
used Survival Analysis test (Figure 4) to analize data related to the follow-up period. 
 
4. Results 
4.1 Study patients 
From June 2016, through December 2016, a total of 30 patients entered in the run-in period. All patients fulfilled the 
criteria for the study. No patients underwent randomization erroneously or were enrolled at sites that were closed 
owing to serious Good Clinical Practice Violations. Most patients were receiving a recommended pharmacologic 
therapy for hypertension disease. At the end of the treatment we obtained a statistically significant correlation about 
improvement of  use of CoraMaPiCC protocol and low presence of procedural complication confronted with data 
reported in the literature.  
 
4.2 Study drug administration and follow-up 
Except for discontinuations owing to death, the study drugs was continued in all patients. The median duration of 
follow-up was 3 month (2 month+1 month). This value was related to the clinical conditions and the presence of 
patient and /or caregiver compliance to the follow-up phase. 
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4.3 Study outcome 
All patients enrolled in the CoRaMaPiCC protocol show a reduction of the trombotic risk if compared with data 
presented in the literature (Gonsalves, Eschei  et al. 2003 and Ong, Gibbs et al. 2006), in both group with normal or 
mutate MTHFR and Homocysteine profile (Figure 1a-b) and different thrombotic or bledding score evaluated with 
CHADSVASC and HASBLED score (Figure 3a-b).  
 
4.4 Safety 
Treatment was effective and well-tolerated when used in routine clinical practice.  
 
5. Results 
The CoRaMaPicc protocol allows, based on the estimation of the preliminary data, to clearly minimize the trombotic 
risk. Our study was designed to provide evidence to support the efficacy of the CoRaMaPiCC protocol in the 
management of frailty patients with comorbidity and absence of vein access [8]. Data shows that the treatment 
improves the patient’s quality of life, reduce the hospedalization period and, therefore, improves the patient’s  
adherence to therapy. This experience led us to use CoRaMaPiCC protocol in patients that have the need to undergo 
a PICC insertion. The protocol was efficacy and well-tollerated when used in routine clinical practice. 
 
The positioning of the device by ultrasound study consent an adeguate evaluation pre and post procedure. A 
radiographic control has allowed that the control procedures can have some limitations. It is beneficial to integrate 
the CoRaMaPiCC Protocol with the Intracavitary ECG (not available during the study) in the presence of 
contraindications for ultrasound evaluation (meteorism) or radiographic evaluation (ascites in forced decupitus). In 
the first case the ultrasound examination was replaced by the radiographic evaluation. In the second case is not 
possible to execute a radiographic control, therefore, the evaluation of the functionality of the device was deduced 
using the only ultrasound approach, with the limits of the ultrasound method. In effect in a patient, an adequate 
Thorax radiographic assessment was not possible because of the poor collaboration due to the presence of ascites 
(even after drainage with 5000cc evacuation paracentesis) and the X-ray procedure can be performed in the only 
lateral decoupled to evoid dyspnoea (decupid on the right side). 
 
6. Discussion 
Intravenous therapy can be administered using different intravascular devices with specific indications that must be 
identified. The use of the Peripherally Inserted Central Catheter (PICC) has been significantly increased, being 
considered a safe method for long-term administration of antibiotics, chemotherapy [9], parenteral nutrition, both in 
the hospital and in the treatment house. The PICC is a central venous system inserted peripherally for continuous 
and discontinuous use for a period of time ranging from 1 week to 3 months. It is made up of last-generation high-
biocompatibility, silicone or polyurethane materials, of 40-60 cm in length, ranging between 16 and 25 G or 2 and 5 
Fr. The PICC allows all the typical uses of central venous catheters ( CVC), inserted in succlavia and giugulare, but 
with respect to these, has the following advantages of avoiding the risk of mechanical insertion complications, 
typical of direct central venous puncture (eg hemo-pneumothorax), low risk of bacterial complications, low risk of 
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central venous thrombosis, it can be positioned by medical or nursing personnel with adequate trainer period without 
an anesthesiologic or surgical specialistic formation, it can also be used discontinuously, without increasing the risk 
of obstructive or infectious complications. From the data in the literature, the presence of non-eliminable risk factors 
(i.e. anatomical configuration of the vein) play a secondary role in the evaluation of the procedural risk factors.  
 
The gold standard to certify the correct positioning of the tip of the device results is a RX chest post-implant. During 
the study period (1 year), the PICCs were removed for death (7 patients; 4 patients for irreversible heart disease, 1 
patient for cardiogenic shock, 1 patient for septic shock [10], 1 patient for Creutzfeld-Jacob disease, 1 patient for 
spontaneously remotion due to the low compliance of the patient. In the other cases, the PICC were removed for end 
of therapy (22 patients) (Figure 4). Only a scrupolous PICC insertion protocol and a meticulous management of the 
dispositive (like a wash-out with 5 cc (ml) of saline solution using a 10 cc (ml) syringe after any pharmacological 
treatment) can minimize the thrombotic risk respect to the data reported in the international literature.  
 
7. Conclusion 
The CoRaMaPicc protocol, which we have elaborated, allows, based on the estimation of preliminary data, to 
minimize the trombotic risk. Further studies are needed to expand the number of enrolled patients and to prolong 
their follow-up period. Our data gives comfortable results but further evaluation are needed to have conclusive 
results.  
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